Off-Label Prescribing of Medications for COVID-19
Effective Jan 4, 2022These Regulations are promulgated pursuant to the authority conferred under R.I. Gen. Laws §§ 23-1-1 and 23-1-18 and are established for the purpose of allowing off-label prescribing to treat COVID-19.Department of Health
6.1 Authority
- These Regulations are promulgated pursuant to the authority conferred under R.I. Gen. Laws §§ 23-1-1 and 23-1-18 and are established for the purpose of allowing off-label prescribing to treat COVID-19.
6.2 Definitions
A. Wherever used in this Part, the terms listed below shall be construed in the following manner:
- 1. "COVID-19" means the disease caused by novel coronavirus SARS-CoV-2.
- 2. "Off-label prescribing" means the prescribing of an FDA-approved medication for reasons other than indicated or approved by the FDA.
- 3. "Practitioner" means any person licensed in the state of Rhode Island to provide health care services and to prescribe medication.
6.3 Off-Label Prescribing of Medications for Treatment or Prevention of COVID-19
- A. No practitioner shall prescribe any medication for COVID-19, either for treatment or prevention, unless treatment or prevention of COVID-19, or similar infectious disease, is within such practitioner's usual and customary scope of practice.
B. Any practitioner who chooses to prescribe an FDA-approved medication for the off-label purpose of treating COVID-19 shall:
- 1. Indicate on the prescription the applicable ICD-10 diagnosis code.
- 2. Indicate on the prescription a telephone number at which the dispensing authority (e.g., pharmacist) may reach the health care provider to address questions relative to dose and treatment.
- 3. Document in the associated patient's medical record that the specific risks and benefits of the off-label treatment were discussed with the patient.
4. Document in the associated patient's medical record the clinical rationale for the off-label prescribing, citing:
- a. At least one (1) peer-reviewed article that justifies the clinical decision for the off-label prescribing, in the event that the FDA publishes such guidance; or
- b. Applicable FDA guidance justifying the clinical decision for the off-label prescribing, in the event that the FDA publishes such guidance.
- C. This Part does not apply to physicians licensed to practice medicine in the state of Rhode Island pursuant to R.I. Gen. Laws Chapter 5-37, who are board certified in the American Board of Medical Specialties (ABMS) specialties of Infectious Disease and/or Critical Care.